Inflammatory Disease News and Research

RSS

Final results from Vertex VX-509 Phase 2a study on RA

Vertex Pharmaceuticals Incorporated today announced the final results from a Phase 2a study of the investigational selective oral JAK3 inhibitor VX-509.

6 Nov 2011

Psychological stress can trigger flares of vasculitis

In patients with a devastating form of vasculitis who are in remission, stress can be associated with a greater likelihood of the disease flaring, according to a new study by investigators at Hospital for Special Surgery.

6 Nov 2011

Idera raises $9.5M in convertible preferred stock offering

Idera Pharmaceuticals, Inc. today announced it has raised $9.5 million in a convertible preferred stock offering.

5 Nov 2011

Teva reports data from QNASL studies on seasonal and perennial allergic rhinitis

Teva Pharmaceutical Industries Ltd. today announced that data from four late-stage studies examining QNASL (beclomethasone dipropionate [BDP]) HFA, a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) symptoms, will be presented at the 2011 Annual Meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Boston, Mass., November 3-8, 2011.

1 Nov 2011

Initiation of two IPI-145 Phase 1 clinical trials triggers $4M milestone payment to Intellikine

Intellikine, Inc., a company focused on the discovery and development of innovative, small molecule drugs targeting the PI3K/mTOR pathway, announced today that it has earned $4 million in milestone payments upon the initiation of two Phase 1 clinical trials of IPI-145.

31 Oct 2011

'Good bugs' promising against ulcerative colitis, psoriasis, chronic fatigue syndrome

In four different studies presented at the American College of Gastroenterology's (ACG) 76th Annual Scientific meeting in Washington, DC, researchers explored the effectiveness of probiotics for antibiotic-associated diarrhea; as an anti-inflammatory agent for patients with ulcerative colitis, psoriasis and chronic fatigue syndrome; and for people with abdominal discomfort and bloating who have not been diagnosed with a functional bowel disorder, such as irritable bowel syndrome (IBS).

31 Oct 2011

Infinity commences two IPI-145 Phase 1 clinical trials for hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced that it has initiated two Phase 1 clinical trials of IPI-145, a potent, orally available inhibitor of phosphoinositide-3-kinase (PI3K) delta and gamma. These two enzymes are implicated in hematologic cancers as well as a broad range of inflammatory conditions, which are the areas of focus within Infinity's PI3K clinical development program.

31 Oct 2011

HAL Allergy initiates PURETHAL Mites PHASE II study

HAL Allergy B.V. today announced that it has included the first patient in its PHASE II dose range finding study.

31 Oct 2011

First Edition: October 28, 2011

In today's headlines, reports about the health law's public support, the latest on the super committee and news about the cost of Medicare Part B premiums.

28 Oct 2011

Impact of pelvic inflammatory disease on teen girls underestimated

A Johns Hopkins Children's Center study comparing perceptions of pelvic inflammatory disease (PID) among teen girls and parents has found that parents seriously underestimate the emotional and medical impact this sexually transmitted disease has on teenagers.

28 Oct 2011

African-Americans have higher burden of multiple, large-joint OA

New research suggests African Americans have a higher burden of multiple, large-joint osteoarthritis (OA), and may not be recognized based on the current definition of "generalized OA."

21 Oct 2011

Breakthrough in the study of chlamydia genetics

A breakthrough in the study of chlamydia genetics could open the way to new treatments and the development of a vaccine for this sexually transmitted disease.

13 Oct 2011

Potential vaccine against trachoma

An attenuated, or weakened, strain of Chlamydia trachomatis bacteria can be used as a vaccine to prevent or reduce the severity of trachoma, the world's leading cause of infectious blindness, suggest findings from a National Institutes of Health study in monkeys.

10 Oct 2011

UNC researchers reveal genetic underpinnings of Foxp3-expressing regulatory T cells

Within the immune system, a subtle balance exists between the cells that destroy alien pathogens and those that preserve the body's own tissues. When the balance gets out of whack, the cells that normally target viruses or bacteria can go astray, attacking innocent cells and causing autoimmune and inflammatory disease.

20 Sep 2011

Novartis reports positive results from first pivotal ACZ885 Phase III trial in systemic juvenile idiopathic arthritis

Novartis announced today positive results of the first pivotal Phase III trial of ACZ885 in patients with systemic juvenile idiopathic arthritis (SJIA), a rare and serious childhood auto-inflammatory disease. The results, presented at the 2011 European Pediatric Rheumatology Congress in Bruges, Belgium, showed all primary and secondary endpoints of the study were met.

17 Sep 2011

Cam impingement may increase risk of hip OA in young men

Hip impingement may be a risk factor of osteoarthritis (OA) of the hip. A new study reveals that the presence of an underlying deformity, known as cam impingement, is associated with hip damage in young men without any arthritis symptoms and detected using magnetic resonance imaging.

8 Sep 2011

Scientists discover 29 new genetic variants linked with MS

Multiple sclerosis is primarily an immunological disease. Scientists at Charité - Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine (MDC) have in succeeded, in collaboration with 23 research teams from 15 different countries, in discovering a total of 29 new genetic variants that are involved in the genesis of multiple sclerosis (MS), an inflammatory disease of the nervous system.

7 Sep 2011

Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints

Vertex Pharmaceuticals Incorporated today announced that treatment with the investigational selective oral JAK3 inhibitor VX-509 in a Phase 2a trial resulted in substantial and statistically significant improvements in multiple measurements of rheumatoid arthritis (RA) activity.

6 Sep 2011

Chondroitin sulfate decreases pain and improves hand function in patients with OA

New research shows that chondroitin sulfate significantly decreased pain and improved hand function in patients with osteoarthritis (OA) of the hand compared with those in the placebo group. Results of the clinical trial available today in Arthritis & Rheumatism, a journal published by Wiley-Blackwell on behalf of the American College of Rheumatology (ACR), also report that chondroitin sulfate improves grip strength and relieves morning stiffness.

6 Sep 2011

Toclizumab for juvenile rheumatoid arthritis

The arthritis drug Toclizumab could be a boon for hundreds of children suffering from severe arthritis. It has been re-launched in children after being already licensed for the treatment of adults. At least two thirds of children taking tocizilumab have been able to return to a normal life, after many were bedridden or forced into wheelchairs by the disease, the clinical studies reveal.

16 Aug 2011

Inflammatory Disease News and Research

Final results from Vertex VX-509 Phase 2a study on RA

Psychological stress can trigger flares of vasculitis

Idera raises $9.5M in convertible preferred stock offering

Teva reports data from QNASL studies on seasonal and perennial allergic rhinitis

Initiation of two IPI-145 Phase 1 clinical trials triggers $4M milestone payment to Intellikine

'Good bugs' promising against ulcerative colitis, psoriasis, chronic fatigue syndrome

Infinity commences two IPI-145 Phase 1 clinical trials for hematologic malignancies

HAL Allergy initiates PURETHAL Mites PHASE II study

First Edition: October 28, 2011

Impact of pelvic inflammatory disease on teen girls underestimated

African-Americans have higher burden of multiple, large-joint OA

Breakthrough in the study of chlamydia genetics

Potential vaccine against trachoma

UNC researchers reveal genetic underpinnings of Foxp3-expressing regulatory T cells

Novartis reports positive results from first pivotal ACZ885 Phase III trial in systemic juvenile idiopathic arthritis

Cam impingement may increase risk of hip OA in young men

Scientists discover 29 new genetic variants linked with MS

Vertex VX-509 12-week Phase 2a study on RA meets two primary endpoints

Chondroitin sulfate decreases pain and improves hand function in patients with OA

Toclizumab for juvenile rheumatoid arthritis

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News